[11C]UCB-J radiotracer for Schizophrenia

Phase-Based Estimates
1
Effectiveness
1
Safety
Stanford University, Stanford, CA
Schizophrenia
[11C]UCB-J radiotracer - Drug
Eligibility
18+
All Sexes
Eligible conditions
Schizophrenia

Study Summary

This study is evaluating whether there is a difference in synaptic density between people with schizophrenia and healthy controls.

See full description

Treatment Effectiveness

Effectiveness Estimate

1 of 3

Compared to trials

Study Objectives

This trial is evaluating whether [11C]UCB-J radiotracer will improve 1 primary outcome in patients with Schizophrenia. Measurement will happen over the course of 120 minutes (scan duration).

120 minutes (scan duration)
Cross-sectional differences in synaptic density between HC and SZ participants

Trial Safety

Safety Estimate

1 of 3

Compared to trials

Trial Design

2 Treatment Groups

No Control Group
Schizophrenia (SZ) Participants

This trial requires 60 total participants across 2 different treatment groups

This trial involves 2 different treatments. [11C]UCB-J Radiotracer is the primary treatment being studied. Participants will be divided into 2 treatment groups. There is no placebo group. The treatments being tested are in Phase 1 and are in the first stage of evaluation with people.

Schizophrenia (SZ) ParticipantsParticipants will undergo positron emission tomography-magnetic resonance (PET-MR) imaging using the [11C]UCB-J radiotracer
Healthy Control (HC) ParticipantsParticipants will undergo positron emission tomography-magnetic resonance (PET-MR) imaging using the [11C]UCB-J radiotracer

Trial Logistics

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 120 minutes (scan duration)
This trial has the following approximate timeline: 3 weeks for initial screening, variable treatment timelines, and roughly 120 minutes (scan duration) for reporting.

Who is running the study

Principal Investigator
J. Y.
Prof. Jong Yoon, Associate Professor of Psychiatry and Behavioral Sciences
Stanford University

Closest Location

Stanford University - Stanford, CA

Eligibility Criteria

This trial is for patients born any sex aged 18 and older. There are 4 eligibility criteria to participate in this trial as listed below.

Mark “yes” if the following statements are true for you:
18 - 65 years in age
On a stable medication regimen for at least two weeks prior to testing
A clinical diagnosis of schizophrenia, schizophreniform, or schizoaffective disorder
Able to complete a PET-MR scan without the use of sedation

Patient Q&A Section

Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Can schizophrenia be cured?

Add answer

Although some patients may experience some improvement, there is no absolute proof that schizophrenia can be cured. However, significant advances are being made in understanding neural mechanisms of psychosis.

Unverified Answer

How many people get schizophrenia a year in the United States?

Add answer

There are a variety of factors affecting annual incidence of schizophrenia. One is the age at which the first psychosis occurs. A later age at onset has been associated with a higher rate of incidence, but this effect appears to operate through a mechanism other than the natural course of schizophrenia. Other factors may influence the incidence of schizophrenic psychosis through some effect on the vulnerability to the illness, such as genetic susceptibility or neurodevelopmental insult.

Unverified Answer

What is schizophrenia?

Add answer

Schizophrenia is sometimes defined as a specific mental disorder that is characterised by profound and unusual symptoms accompanied by disorganisation of thought, speech, and behaviour, which are not attributable to the direct effects of a drug or physical disease. When the presentation resembles some other mental disorder, such as the mood disorders depression and anxiety, the use of other descriptive terms such as psychotic, disordered, or bizarre is more appropriate.\n

Unverified Answer

What are common treatments for schizophrenia?

Add answer

This review indicates that pharmacological treatments prevail, with multiple lines of medication for each type of disorder. The main pharmacological treatment for schizophrenia is antipsychotic medication.

Unverified Answer

What are the signs of schizophrenia?

Add answer

The signs of schizophrenia are varied and nonspecific. The symptoms of schizophrenia have a wide range in presentation. Schizophrenia can be associated with a variety of physical signs such as skin changes and lymph node enlargement. The signs of schizophrenia can be divided into nonspecific and specific signs. The nonspecific manifestations are associated with many other physical signs and complaints of patients with schizophrenia. The specific signs are associated with certain physical disorders.

Unverified Answer

What causes schizophrenia?

Add answer

There is no single, single etiological cause of schizophrenia, and the development of schizophrenia is probably multifactorial. However, common factors such as environmental factors, infection, genetics, and the immune system may play important roles in the development of schizophrenia, and the genetic component of schizophrenia is significant.

Unverified Answer

What is the latest research for schizophrenia?

Add answer

Recent research into the underlying causes of schizophrenia continues to provide new information into this complex phenomenon. The potential to clarify pathogenic mechanisms in schizophrenia is very real. It is estimated that a new generation of anti-psychotics with potent and selective pharmacological properties will soon be available to patients, a potential dramatic breakthrough for people suffering from this disease.

Unverified Answer

What is the primary cause of schizophrenia?

Add answer

The primary cause of schizophrenia which is in essence atypical of schizophrenia may be traced into a number of things including the influence of parenting, the influence of sex/gender on the course of the illness, one's genetic makeup, epigenetic modifications and the influence of viruses.

Unverified Answer

How does [11c]ucb-j radiotracer work?

Add answer

[11C]ucb-j PET provides a powerful tool to assess BZD binding. We will show that SNC81-3 binds preferentially to high-affinity BZD receptors and that SNC81-3 may be of practical value for defining high- and low-affinity binding sites in the human brain.

Unverified Answer

Have there been any new discoveries for treating schizophrenia?

Add answer

Although there are multiple treatment options available to patients with schizophrenia, there is no single treatment found to be the right and best approach; rather, each patient needs unique treatment based on the signs and symptoms, age, and any other individual or contextual factors. New treatments may arise for the treatment of schizophrenia. We are only beginning to understand its complexity and the many causes.

Unverified Answer

Does schizophrenia run in families?

Add answer

As families are regarded as being in the best position to prevent the occurrence of schizophrenic disorders, the answer is a big, yes, so we need to start looking for more genetic factors that are not currently being explored. One area to look at is the role that family stressors and early experiences can play in the development of schizophrenia. The influence of specific family factors, such as family discord, is another issue that merits scrutiny.

Unverified Answer

Is [11c]ucb-j radiotracer typically used in combination with any other treatments?

Add answer

The combination of [11C]ucb-j with cognitive behavioral or pharmacological treatment may provide some advantages over cognitive-only treatment or monotherapy (e.g., an advantage in symptom severity or quality of life).

Unverified Answer
See if you qualify for this trial
Get access to this novel treatment for Schizophrenia by sharing your contact details with the study coordinator.